Terns Pharmaceuticals to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that management will be participating in a liver disease panel at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10 at 2:20pm ET. Terns management will also present at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at 1:00pm ET.

A live webcast of the events will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for 30 days following the presentations.

About Terns PharmaceuticalsTerns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns’ pipeline includes three clinical stage development programs including an FXR agonist, a VAP-1 inhibitor and a THR-β agonist, and a preclinical GLP-1 receptor agonist program. Terns is focused on developing combination therapies based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
[email protected]

Media
Jenna Urban
Berry & Company Public Relations
[email protected]

You May Also Be Interested In

• Apple TV's 'Acapulco,' Andy Garcia Lead Winners and Honorees at '41st Annual Imagen Awards' Celebrating Latino Entertainment
• Solana Cuts Block Times Toward 200ms, Is AlphaPepe the Best Crypto To Buy Now for Bigger Upside?
• SuperiorMed Holdings Limited Announces Entering into an Agreement and Plan of Merger with Starry Sea Acquisition Corp